Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
37 participants
INTERVENTIONAL
2016-12-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The first phase will consist of ten (10) subjects enrolled and treated using the SoundBite Crossing System with 30 day follow-up. An analysis shall be performed after 10 subjects undergo treatment with the SoundBite Crossing System and complete 30 day follow-up. This analysis shall be utilized to provide insight into product performance and safety.
The second phase will consist of up to forty (40) subjects enrolled and treated using the SoundBite Crossing System with 30 day follow-up. An analysis will be generated on this subject cohort after 30 day follow-up is complete.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTO Crossing
With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
CTO Crossing
With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CTO Crossing
With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Rutherford Category of 2-5.
3. ≥ 18 years of age.
4. Life expectancy \> 1 year.
5. Able and willing to provide written informed consent prior to study procedure.
6. Evidence that the target CTO lesion is a de novo or restenotic chronic total occlusion in the SFA (starting at least 1cm distal to the origin of the SFA) and/or popliteal artery (ending at least 1cm proximal to the popliteal trifurcation), confirmed by angiography; AND/OR Evidence that the target CTO lesion is a de novo or restenotic chronic total occlusion and is located below the popliteal trifurcation in the anterior tibial, posterior tibial or peroneal arteries (at least 1 cm distal to the vessel origin, and ending at least 1cm proximal to the dorsalis pedis or plantar arteries), confirmed by angiography.
7. Target CTO lesion is 100% occluded by visual estimate.
8. Target limb has at least one patent (\<50% stenosis) tibio-peroneal run-off vessel to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA) or computed tomography angiography (CTA).
9. Target CTO lesion has a cumulative lesion length of no more than 40 cm and terminates at least 1 cm above the ankle or tibio-talar joint.
10. Reference vessel diameter, by visual estimate, is ≥ 4 mm for femoral-popliteal arteries, or ≥ 2 mm for tibial or peroneal arteries.
Exclusion Criteria
2. History of receiving a kidney transplant.
3. Current significant acute or chronic kidney disease with a creatinine level \> 220 micromoles/Land/or requiring dialysis.
4. Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb.
5. History of an endovascular procedure or open vascular surgery on the index limb within the 30 days prior to enrollment.
6. Any planned surgical or interventional procedure within 30 days after the index procedure.
7. Unstable coronary artery disease or other uncontrolled comorbidity.
8. Myocardial infarction or stroke within 3 months prior to enrollment.
9. Currently pregnant or breast-feeding.
10. Participating in any study of an investigational device, medication, biologic, or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgement of the Investigator, affect the results of this study.
11. Known significant stenosis or occlusion of inflow tract (upstream disease) not successfully treated before index procedure.
12. Contraindication to antiplatelet medications, anticoagulant medication, or thrombolytic therapy.
13. Current uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter, known coagulopathy, or INR \>1.5.
14. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
15. History of heparin-induced thrombocytopenia (HIT).
16. Received thrombolytic therapy within two weeks of enrollment.
17. Known psychiatric disorder which in the judgement of the Investigator could interfere with provision of informed consent, completion of tests, therapy, or follow-up.
18. Clinical/angiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of SoundBite Crossing System.
19. Acute or sub-acute intraluminal thrombus within the target vessel.
20. Aneurysm (at least twice the reference vessel diameter) located in the target vessel or popliteal artery.
21. Perforation, dissection or other injury of the access or target vessel requiring stenting or surgical intervention.
22. Clinical/angiographic evidence of distal embolization in the target limb.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SoundBite Medical Solutions, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Benko, MD
Role: PRINCIPAL_INVESTIGATOR
CHUS - Centre Hospitalier Universitaire de Sherbrooke - Fleurimont
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUM - Centre Hospitalier de l'Université de Montreal - Hôtel-Dieu
Montreal, Quebec, Canada
CHUS - Centre Hospitalier Universitaire de Sherbrooke - Freurimont
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-PER-2015-01
Identifier Type: -
Identifier Source: org_study_id